• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苏氨酸寡肽酶(EC 3.4.24.15)可激活CPI-0004Na,一种细胞外肿瘤激活的阿霉素前药。

Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin.

作者信息

Dubois V, Nieder M, Collot F, Negrouk A, Nguyen T T, Gangwar S, Reitz B, Wattiez R, Dasnois L, Trouet A

机构信息

Université Catholique de Louvain, Laboratory of Cell Biology, Place Croix du Sud 5, 1348 Louvain-La-Neuve, Belgium.

出版信息

Eur J Cancer. 2006 Nov;42(17):3049-56. doi: 10.1016/j.ejca.2005.10.030. Epub 2006 Apr 27.

DOI:10.1016/j.ejca.2005.10.030
PMID:16644202
Abstract

CPI-0004Na is a tetrapeptidic extracellularly tumour-activated prodrug of doxorubicin. The tetrapeptide structure ensures blood stability and selective cleavage by unidentified peptidase(s) released by tumour cells. The purpose of this work was to identify the enzyme responsible for the first rate-limiting step of CPI-0004Na activation, initially attributed to a 70 kDa acidic (pI=5.2) metallopeptidase active at neutral pH that was subsequently purified from HeLa cell homogenates. Two electrophoretic bands were isolated and identified by matrix-assisted laser desorption ionisation-time of flight (MALDI-tof) and electrospray ionisation-quadrupole-time of flight (ESI-Q-tof) mass spectrometry as thimet oligopeptidase (TOP). The identity of the CPI-0004Na activating enzyme and TOP was further supported by the similar substrate specificity of the purified enzyme and recombinant TOP, by thiol stimulation of CPI-0004Na cleavage by cancer cell conditioned media (unique characteristic of TOP) and by the inhibition of CPI-0004Na activation by specific inhibitors or immunoprecipitation. Although other enzymes can be involved, TOP clearly appears to be a likely candidate for extracellular activation of the CPI-0004Na prodrug.

摘要

CPI-0004Na是一种四肽类细胞外肿瘤激活的阿霉素前药。四肽结构确保了血液稳定性以及被肿瘤细胞释放的未知肽酶进行选择性切割。这项工作的目的是鉴定负责CPI-0004Na激活第一步限速步骤的酶,最初认为是一种70 kDa的酸性(pI = 5.2)金属肽酶,在中性pH下具有活性,随后从HeLa细胞匀浆中纯化得到。通过基质辅助激光解吸电离飞行时间(MALDI-tof)和电喷雾电离四极杆飞行时间(ESI-Q-tof)质谱法分离并鉴定出两条电泳带为硫醇寡肽酶(TOP)。纯化酶和重组TOP具有相似的底物特异性、癌细胞条件培养基对CPI-0004Na切割的硫醇刺激作用(TOP的独特特征)以及特异性抑制剂或免疫沉淀对CPI-0004Na激活的抑制作用,进一步支持了CPI-0004Na激活酶与TOP的一致性。尽管可能涉及其他酶,但TOP显然是CPI-0004Na前药细胞外激活的一个可能候选者。

相似文献

1
Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin.苏氨酸寡肽酶(EC 3.4.24.15)可激活CPI-0004Na,一种细胞外肿瘤激活的阿霉素前药。
Eur J Cancer. 2006 Nov;42(17):3049-56. doi: 10.1016/j.ejca.2005.10.030. Epub 2006 Apr 27.
2
CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.CD10是参与肿瘤激活肽前药CPI-0004Na及其新型类似物激活的关键酶:对设计用于治疗CD10+肿瘤的新型肽前药的启示。
Cancer Res. 2003 Sep 1;63(17):5526-31.
3
CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.CPI-0004Na,一种新型的细胞外肿瘤激活阿霉素前体药物:体内毒性、活性和组织分布证实了肿瘤细胞选择性。
Cancer Res. 2002 Apr 15;62(8):2327-31.
4
CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice.CPI-0004Na,一种新型阿霉素前体药物,可抑制C57BI/6小鼠体内3LL-H61肺癌转移灶的生长。
J Exp Ther Oncol. 2004 Jul;4(2):167-9.
5
Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.多柔比星肿瘤选择性肽前药DTS-201的临床前毒性、毒代动力学及抗肿瘤疗效研究
Clin Cancer Res. 2008 Feb 15;14(4):1258-65. doi: 10.1158/1078-0432.CCR-07-1165.
6
Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.具有丙氨酸-亮氨酸-丙氨酸-亮氨酸连接子、可被组织蛋白酶B裂解的喜树碱和阿霉素白蛋白结合前药:合成与抗肿瘤疗效
Bioconjug Chem. 2007 May-Jun;18(3):702-16. doi: 10.1021/bc0602735. Epub 2007 Mar 23.
7
Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.用于癌症选择性化疗的细胞外肿瘤激活前药:阿霉素的应用及初步体外和体内研究
Cancer Res. 2001 Apr 1;61(7):2843-6.
8
Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.将细胞不可渗透的前药激活靶向肿瘤微环境可根除多种耐药性肿瘤。
Cancer Res. 2006 Jan 15;66(2):970-80. doi: 10.1158/0008-5472.CAN-05-2591.
9
Enzyme-catalyzed activation of anticancer prodrugs.酶催化的抗癌前药激活
Pharmacol Rev. 2004 Mar;56(1):53-102. doi: 10.1124/pr.56.1.3.
10
Characterization of thiol-, aspartyl-, and thiol-metallo-peptidase activities in Madin-Darby canine kidney cells.
J Cell Biochem. 2000 Jan;76(3):478-88.

引用本文的文献

1
PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index.PhAc-ALGP-Dox,一种具有靶向激活和改善治疗指数的新型抗癌前药。
Mol Cancer Ther. 2022 Apr 1;21(4):568-581. doi: 10.1158/1535-7163.MCT-21-0518.
2
Expression of THOP1 and its relationship to prognosis in non-small cell lung cancer.THOP1在非小细胞肺癌中的表达及其与预后的关系。
PLoS One. 2014 Sep 2;9(9):e106665. doi: 10.1371/journal.pone.0106665. eCollection 2014.
3
Protease-activated drug development.蛋白酶激活药物研发。
Theranostics. 2012;2(2):156-78. doi: 10.7150/thno.4068. Epub 2012 Feb 8.